Anti-hPD-L1-mIgG1 features the variable region of atezolizumab, a therapeutic monoclonal antibody (mAb) that targets human PD-L1, blocking the interaction with its receptor PD-1. Atezolizumab (formerly known as MPDL3280A) is a fully humanized IgG1 mAb with a modified Fc region designed to limit antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [1, 2]. It contains a N298A mutation that eliminates its ability to bind to human Fcγ receptors.
In contrast to nivolumab, a therapeutic mAb that targets only human PD-1, atezolizumab targets both human and mouse PD-L1. To enable studies in mice, the human effectorless Fc domain of atezolizumab has been replaced by the Fc domain of mouse IgG1, an isotype exhibiting low CDC and no ADCC.
Anti-hPD-L1-mIgG1 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.

Anti-hPD-L1-mIgG1 InvivoFit™ is specifically designed for mouse studies:

  • Contains a mouse IgG1 Fc domain to prevent ADAs (anti-drug-antibodies)
  • Provided in a large unit size (5 x 1 mg), larger quantities are available
  • Guaranteed sterile
  • Endotoxin level
  • Low aggregation, < 5%
  • No preservative
  • Binding validated by flow cytometry using EL4 cells expressing membrane bound mouse PD-L1


Specificity: Targets cells expressing human and mouse PD-L1
Clonality: Monoclonal antibody
Isotype: Mouse IgG1
Source: CHO cells
Purity: Purified by affinity chromatography with protein G


• 100 µg purified anti-hPD-L1-mIgG1 antibody, provided azide-free and lyophilized


• 5 x 1 mg purified anti-hPD-L1-mIgG1 InvivoFit™ antibody, provided sterile, endotoxin-free, azide-free and lyophilized



1. Spigel D. et al., 2013. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract 8008]. J Clin Oncol. 31(15)(suppl).
2. Herbst RS. et al., 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515(7528):563-7.



Description Human PD-L1 (atezolizumab) antibody - Mouse IgG1
Cat. Codehpdl1-mab9
Unit Size100 µg
Price For price or distributor address,
please select your country

Anti-hPD-L1-mIgG1 InvivoFit

Description Human PD-L1 (atezolizumab) antibody - Mouse IgG1
Cat. Codehpdl1-mab9-5
Unit Size5 x 1 mg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".